Organogenesis (ORGO) launches at-the-market offering of up to $75M of Class A common stock

Filed August 6, 2026 · ~2 min read

Key Changes

• high

  At-the-market offering of up to $75M of Class A common stock with no fixed price or minimum; shares sold from time to time at prevailing market prices. At the $2.37 reference price (August 5, 2026 close), the full offering would be 31.6M shares.

  The Offering verify on EDGAR →
• high

  Implied post-offering market capitalization of $380.0M at the $2.37 reference price (160.3M shares outstanding after the offering). New investors would experience immediate dilution of $0.32 per share versus the company's $2.05 as-adjusted net tangible book value.

  Dilution verify on EDGAR →
• medium

  Proceeds for working capital and general corporate purposes, including facility expansion, manufacturing enhancements, salesforce expansion, clinical studies, regulatory approvals, and obtaining commercial insurance coverage for products.

  Use of Proceeds verify on EDGAR →